Home > Healthcare > Pharmaceuticals > Vaccines > Ebola Virus Vaccine Market

Ebola Virus Vaccine Market Trends

Report ID: GMI6083
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Ebola Virus Vaccine Market Trends

Increasing research and development efforts for Ebola virus vaccine development is expected to significantly driver the market growth. Various pharmaceutical companies, research institutions and organizations are investing in R&D activities to advance the development of effective vaccines against infectious diseases including Ebola. For instance, in 2021, Bavarian Nordic and Johnson & Johnson partnered to support efforts by the World Health Organization (WHO) to prevent further spread of Ebola in West Africa through the donation of up to 200,000 courses of the Johnson & Johnson Ebola vaccine regimen. Thus, the growing demand to prevent the spread of Ebola in West African countries is expected to drive the market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Ebola virus vaccine market accounted for USD 4.4 million in 2022 and is estimated to grow at 32.6% CAGR through 2032, driven by the growing incidence of zoonotic diseases across the globe.

Hospitals segment accounted for USD 1.6 million market revenue in 2022, owing to the availability of skilled medical professionals, better accessibility & convenience, and advanced healthcare infrastructure.

U.S. Ebola virus vaccine market accounted for over 52.3% revenue share in 2022 and will grow at a considerable rate through 2032, backed by the growing demand for preventive healthcare, and rising government investments to create awareness regarding vaccination and controlling outbreaks.

Merck & Co., Inc, Johnson & Johnson, Bavarian Nordic, GlaxoSmithKline plc among others.